The effect of surgery in tenosynovial giant cell tumours as measured by patient-reported outcomes on quality of life and joint function

Bone Joint J. 2019 Mar;101-B(3):272-280. doi: 10.1302/0301-620X.101B3.BJJ-2018-0804.R1.

Abstract

Aims: The aim of this study was to evaluate health-related quality of life (HRQoL) and joint function in tenosynovial giant cell tumour (TGCT) patients before and after surgical treatment.

Patients and methods: This prospective cohort study run in two Dutch referral centres assessed patient-reported outcome measures (PROMs; 36-Item Short-Form Health Survey (SF-36), visual analogue scale (VAS) for pain, and Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC)) in 359 consecutive patients with localized- and diffuse-type TGCT of large joints. Patients with recurrent disease (n = 121) and a wait-and-see policy (n = 32) were excluded. Collected data were analyzed at specified time intervals preoperatively (baseline) and/or postoperatively up to five years.

Results: A total of 206 TGCT patients, 108 localized- and 98 diffuse-type, were analyzed. Median age at diagnosis of localized- and diffuse-type was 41 years (interquartile range (IQR) 29 to 49) and 37 years (IQR 27 to 47), respectively. SF-36 analyses showed statistically significant and clinically relevant deteriorated preoperative and immediate postoperative scores compared with general Dutch population means, depending on subscale and TGCT subtype. After three to six months of follow-up, these scores improved to general population means and continued to be fairly stable over the following years. VAS scores, for both subtypes, showed no statistically significant or clinically relevant differences pre- or postoperatively. In diffuse-type patients, the improvement in median WOMAC score was statistically significant and clinically relevant preoperatively versus six to 24 months postoperatively, and remained up to five years' follow-up.

Conclusion: Patients with TGCT report a better HRQoL and joint function after surgery. Pain scores, which vary hugely between patients and in patients over time, did not improve. A disease-specific PROM would help to decipher the impact of TGCT on patients' daily life and functioning in more detail. Cite this article: Bone Joint J 2019;101-B:272-280.

Keywords: Health-related quality of life; Joint function; Pigmented villonodular synovitis; Surgery; Tenosynovial giant cell tumours.

Publication types

  • Multicenter Study

MeSH terms

  • Activities of Daily Living
  • Adult
  • Female
  • Giant Cell Tumor of Tendon Sheath / rehabilitation
  • Giant Cell Tumor of Tendon Sheath / surgery*
  • Humans
  • Male
  • Middle Aged
  • Neoplasm Recurrence, Local / rehabilitation
  • Neoplasm Recurrence, Local / surgery*
  • Patient Reported Outcome Measures*
  • Prospective Studies
  • Quality of Life*
  • Range of Motion, Articular
  • Recovery of Function